Rheumatology · Systemic Autoimmune Diseases
The facts most likely to be tested
The classic high-risk medications associated with Drug-Induced Lupus (DIL) are procainamide, hydralazine, isoniazid, and quinidine.
Patients with DIL typically present with arthralgias, myalgias, fever, and serositis rather than the severe organ involvement seen in Systemic Lupus Erythematosus (SLE).
The hallmark serologic finding in DIL is the presence of anti-histone antibodies, which are present in over 90% of cases.
Unlike SLE, DIL is characterized by the absence of anti-dsDNA antibodies and anti-Smith antibodies.
DIL is strongly associated with the HLA-DR4 genotype, particularly in patients who are slow acetylators of drugs like hydralazine.
Renal and central nervous system involvement are extremely rare in DIL and should prompt a search for an alternative diagnosis.
The definitive management for DIL is the immediate discontinuation of the offending medication, which typically leads to resolution of symptoms within weeks.
Vignette unlocked
A 62-year-old male presents to the clinic with a 3-week history of joint pain, fatigue, and low-grade fever. He has a history of hypertension and has been taking hydralazine for the past 8 months. Physical examination reveals symmetrical polyarthritis of the small joints of the hands and pleuritic chest pain on deep inspiration. Laboratory studies show a positive antinuclear antibody (ANA) test and a positive anti-histone antibody titer. His anti-dsDNA and anti-Smith antibodies are negative.
What is the most appropriate next step in management?
Discontinuation of hydralazine
The patient's clinical presentation and serologic profile (positive anti-histone, negative anti-dsDNA) are diagnostic for Drug-Induced Lupus, which is managed by stopping the causative agent.
Full handout
High yield triage
Etiology / Epidemiology
Associated with slow acetylator status and chronic use of procainamide, hydralazine, or isoniazid.
Clinical Manifestations
Presents with arthralgias, myalgias, and fever; notably spares the malar rash and renal/CNS systems.
Diagnosis
Anti-histone antibodies are present in >95% of cases; ANA is positive but anti-dsDNA is typically negative.
Treatment
Immediate discontinuation of the offending agent; symptoms usually resolve within weeks.
Prognosis
Excellent prognosis; complete resolution is expected once the drug is withdrawn.
Full handout
Epidemiology & Etiology
Occurs most frequently in patients with slow acetylator status (N-acetyltransferase 2 deficiency). High-risk medications include procainamide, hydralazine, isoniazid, and quinidine. Unlike SLE, there is no strong female predominance, and it is often seen in older adults on long-term therapy.
Pertinent Anatomy
Systemic involvement is limited compared to idiopathic SLE. The serosal surfaces (pleura and pericardium) are the primary sites of inflammation, explaining the common presentation of pleuritis.
Pathophysiology
The drug or its metabolites act as haptens, binding to self-proteins to induce an immune response. This leads to the formation of anti-histone antibodies rather than the anti-dsDNA or anti-Smith antibodies seen in SLE. The process is reversible upon removal of the antigenic stimulus.
Clinical Manifestations
Patients present with constitutional symptoms including fever, fatigue, and weight loss. Arthralgias and myalgias are the most common findings. Pleuritis and pericarditis are frequent, while the malar rash and renal involvement are notably absent.
Diagnosis
The anti-histone antibody test is the most sensitive diagnostic marker. ANA is positive in nearly all cases, but anti-dsDNA and anti-Smith antibodies are typically absent. Complement levels (C3/C4) are usually normal, distinguishing it from active SLE.
Treatment
The primary intervention is the discontinuation of the offending drug. If symptoms are severe, NSAIDs may be used for joint pain, and short-term corticosteroids may be required for serositis. Do not re-challenge with the causative agent once the diagnosis is confirmed.
Prognosis
Prognosis is excellent with complete resolution of symptoms typically occurring within weeks to months. Anti-histone antibodies may persist for months after clinical recovery, so they should not be used to monitor acute disease activity.
Differential Diagnosis
Systemic Lupus Erythematosus: Presence of anti-dsDNA and anti-Smith antibodies
Rheumatoid Arthritis: Symmetric small joint erosions on imaging
Serum Sickness: History of recent vaccination or heterologous protein exposure
Viral Arthritis: Acute onset with associated viral prodrome
Mixed Connective Tissue Disease: Presence of anti-U1 RNP antibodies